BTAI Stock Analysis: Buy, Sell, or Hold?
BTAI - BioXcel Therapeutics, Inc. Common Stock
$1.03
0.15 (16.75%)
▲
5d:
-0.96%
30d:
-7.21%
90d:
+0.98%
BUY
MODERATE Confidence
Analysis Updated: Jul 14, 2026 12:00 AM ET
Earnings: Aug 11, 2026
26d
Get Alerted When BTAI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
4 traders called BTAI this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BTAI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: BTAI shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: BTAI is currently trading at $1.03, which is considered slightly low relative to its 30-day fair value range of $0.98 to $1.32.
Technical Outlook: Technically, BTAI is in a strong uptrend. Immediate support is located at $0.74, while resistance sits at $1.43. The stock is showing strong short-term momentum, up 16.8% recently.
Market Sentiment: BTAI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $14.00 (+1259.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BTAI is in a strong uptrend. Immediate support is located at $0.74, while resistance sits at $1.43. The stock is showing strong short-term momentum, up 16.8% recently.
Market Sentiment: BTAI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $14.00 (+1259.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.98 -
$1.32
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+16.8%)
- BULLISH: Trading 1259.2% below Wall St target ($14.00)
Trading Range Analysis
30-Day Trading Range
$0.98 -
$1.32
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.74
Resistance Level
$1.43
Current Trend
Strong Uptrend
Technical data as of
Jul 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.67
Wall Street Target
$14.00
(+1259.2%)
Revenue Growth (YoY)
22.6%
Share & Embed Analysis
Last updated: July 14, 2026 9:12 PM ET
Data refreshes hourly during market hours. Next update: 10:12 PM
Data refreshes hourly during market hours. Next update: 10:12 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BTAI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$198 | 58 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$116 | 59 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$110 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 58 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$23 | 54 HOLD |
